Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Supernus Pharmaceuticals (SUPN)

Supernus to report Q2 2025 results after market close on August 5, 2025

Neutral Impact 1 of 5 earnings Written later

Supernus Pharmaceuticals said it will report second quarter 2025 financial and business results after the market closes on Tuesday, August 5, 2025. The filing contains no financial results; it sets the date and format for the release and the earnings call.

Key points

  • Results expected after market close on Tuesday, August 5, 2025
  • Conference call and webcast at 4:30 p.m. ET on August 5, 2025, hosted by CEO Jack Khattar and CFO Tim Dec
  • Live webcast on the investor relations website at www.supernus.com/investors; replay available for 60 days after the call

The filing

CompanySupernus Pharmaceuticals (SUPN)
Form8-K, current report
Filed with the SECJul 22, 2025, 4:30 PM ET
Accession number0001356576-25-000046

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 22, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.